Insulin Therapy
Novel once-daily pill reduces HbA1c in type 1 diabetes
An investigational, once-daily pill added to optimized insulin therapy was shown to reduce HbA1c among adults with type 1 diabetes during a 12-week trial when compared with placebo plus insulin, according to a press release from vTv Therapeutics.
Real-world insulin titration support needed for patients, providers
An analysis of two real-world studies comparing standard of care basal insulin therapy with insulin glargine 300 U/mL suggests that more patient and provider support are needed regarding insulin dosing and titration, according to findings published in Current Medical Research and Opinion.
Insulin pump therapy viable option vs. injections for older adults
Older adults with type 1 diabetes may be able to reduce HbA1c and the occurrence of hypoglycemia, diabetic ketoacidosis and hospitalization by using subcutaneous insulin infusion instead of insulin injection therapy, according to findings published in Diabetic Medicine.
Many adults discontinue DPP-IV inhibitor therapy after initiating insulin
More than half of adults with type 2 diabetes prescribed DPP-IV inhibitor therapy discontinued the medications within 1 year of initiating insulin, according to findings from a U.S. health claims database analysis.
Lilly to integrate Dexcom CGM into personalized diabetes devices
Eli Lilly and Dexcom announced a global commercialization agreement to integrate DexCom’s continuous glucose monitoring devices into a personalized diabetes management system currently in development to advance the treatment of diabetes, according to a press release from the companies.
Insulin sensitivity, adiponectin level may predict insulin therapy response in youths with type 2 diabetes
A cohort of youths with obesity and type 2 diabetes who initiated insulin therapy experienced highly variable HbA1c outcomes, with greater insulin sensitivity and higher adiponectin levels associated with improved glycemic response, according to an analysis of the TODAY study.